Skip to main content
Formycon AG logo

Formycon AG — Investor Relations & Filings

Ticker · FYB ISIN · DE000A1EWVY8 LEI · 39120005TZ76GQOY8Z19 F Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2015-07-22 Regulatory Filings
Country DE Germany
Listing F FYB

About Formycon AG

https://www.formycon.com/en/

Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.

Recent filings

Filing Released Lang Actions
Formycon AG receives favorable scientific advice from U.S. Food and Drug Administration for its partnered biosimilar candidate FYB201
Regulatory Filings Classification · 100% confidence The document is a news release dated July 22, 2015, disseminated via DGAP (a service of EQS Group AG). It announces that Formycon AG received favorable scientific advice from the U.S. FDA regarding its biosimilar candidate FYB201. This type of announcement, detailing regulatory feedback or progress in drug development that is not a full financial report (like 10-K or IR) or a specific insider trade/dividend notice, falls best under the general category for regulatory or corporate news that doesn't fit a more specific financial filing code. Since it is a corporate news item about regulatory interaction (FDA advice), and not a formal financial report, it is best classified as a general Regulatory Filing (RNS) or potentially a miscellaneous corporate update. Given the options, RNS serves as the best fallback for significant, non-financial regulatory/corporate news updates that aren't covered by other specific codes like LTR (Legal Proceedings) or CAP (Financing). It is not an ER (Earnings Release) or an IR (Interim Report).
2015-07-22 English
Jahresabschluss 2014
Annual Report Classification · 100% confidence The document is titled 'Geschäftsbericht 2014' (Annual Report 2014) and contains sections typical of a full annual report, such as the balance sheet, profit and loss statement, management report (Lagebericht), and auditor's report (Bestätigungsvermerk des Abschlussprüfers). It also includes a 'Letter to Shareholders' from the CEO and CFO. Given the comprehensive nature of the financial and operational reporting for the full fiscal year 2014, it is classified as an Annual Report. FY 2014
2015-06-08 German
Formycon AG: Results announced for 1Q 2015, forecast raised for full-year 2015
Earnings Release Classification · 100% confidence The document is titled "Formycon AG: Results announced for 1Q 2015, forecast raised for full-year 2015" and explicitly discusses consolidated revenues, EBITDA, and financial performance for the first quarter of 2015. It provides key financial highlights and an updated forecast. This structure strongly indicates an initial announcement of periodic financial results, which aligns with the definition of an Earnings Release (ER). Although it contains some forward-looking statements and context, its primary function is the release of quarterly financial figures, not the comprehensive report itself (which would be an IR) or a transcript (CT). Given the short length (under 5,000 characters) and the nature of the announcement (dissemination of news via DGAP), it is the initial release of results. Q1 2015
2015-06-02 English
Formycon AG signs licensing agreement for its FYB203 biosimilar
Regulatory Filings Classification · 100% confidence The document is a news release dated May 28, 2015, announcing that Formycon AG signed an exclusive, global out-licensing deal for its FYB203 biosimilar drug. It details the financial terms, responsibilities assumed by the partner (Santo Holding), and the strategic implications for Formycon. This type of announcement, detailing a significant corporate transaction (licensing/out-licensing) that impacts future financing and operations, is generally classified as a Corporate News item. Since there is no specific category for 'Licensing Agreement' or 'Corporate Transaction,' and it is not a standard regulatory filing like 10-K, ER, or IR, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement disseminated via a service like DGAP, or potentially 'Capital/Financing Update' (CAP) due to the significant funding secured. However, given the content is primarily about a business deal rather than pure capital structure change or fundraising, RNS is the most appropriate fallback for a significant, non-standard corporate announcement not covered by other specific codes (like M&A, DIV, ER, etc.). The document length (7629 chars) is substantial enough that it is the report itself, not just a notice of a report.
2015-05-28 English
Formycon AG: Carsten Brockmeyer belongs to the top 20 most influential people in the Global 'Medicine Maker Power List' 2015
Board/Management Information Classification · 99% confidence The document is a news release titled "Formycon AG: Carsten Brockmeyer belongs to the top 20 most influential people in the Global ‘Medicine Maker Power List’ 2015". It is distributed via DGAP-News and discusses an external recognition received by the CEO, rather than reporting financial results (ER/IR), providing audited figures (AR), announcing capital changes (CAP/SHA), or detailing management changes (MANG). Since it is a general corporate announcement that doesn't fit the highly specific categories like AGM-R, 10-K, DIRS, or DIV, it falls best under the general Regulatory Filings/News category, which is RNS (Regulatory Filings) as per the provided definitions for miscellaneous announcements.
2015-05-19 English
Formycon AG: Reappointment of board member Dr. Nicolas Combe
Board/Management Information Classification · 100% confidence The document is a news release titled "Formycon AG: Reappointment of board member Dr. Nicolas Combé" and contains keywords like "Supervisory Board," "executive board appointment," and "chief financial officer." This content directly relates to changes in senior management personnel. This aligns perfectly with the definition for Board/Management Information (MANG). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2015-05-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.